Au cœur du développement - NEUTRE vs SOUS REVUE - OC 35€ (vs S.R)
Nous reprenons la couverture de Carmat avec une recommandation NEUTRE et un objectif de 42€/action. La prothèse artificielle est une solution définitive révolutionnaire pour les patients atteints d’insuffisance cardiaque terminale biventriculaire, sur un marché au besoin médical profondément insatisfait. Ses propriétés se prêtent particulièrement à l’amélioration de la qualité de fin de vie des malades. Néanmoins, nous adoptons une posture prudente sur l’issue de l’étude pivot compte tenu du chemin restant à parcourir, sur le calendrier de lancement commercial et nous soulignons les besoins de financement restants. Nous considérons également que la pénétration du marché s’effectuera en trois étapes successives, en fonction de la formation des centres.Carmat is focused on the research and development of an innovative product in the medical sector, developing an orthotopic and biocompatible artificial heart which is completely implantable, as well as its electrical power supply system and remote diagnosis system. Co. is developing a long-term therapeutic solution for patients who suffer from advanced bi-ventricular heart failure and who are not eligible for cardiac transplantation and who have exhausted all drug possibilties. Co. is still in the phase of research and development and thus do not generate any revenues.
Since 2006, Invest Securities has become one of the leading players in investment services for funds and managers, to whom we offer a global and personalised service. Our track record differentiates us and proves our leadership in numerous promising sectors like property and growth companies.
Consisting of 13 different profiles (pharmacist, engineer, financier, etc), the DNA of our financial analysis office is value added and sector expertise. Through daily monitoring and detailed analyses of companies and sectors, we seek to provide a differentiating vision of our 120 stocks followed. Our ideas are circulated every day to nearly 1,000 professionals.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.